Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.

ABSTRACT:

Objectives

Emerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess changes in utilization of these options in Germany with a focus on modern triplet regimens including new agents, such as carfilzomib, ixazomib, elotuzumab and daratumumab, and to evaluate whether this had an impact on rrMM-related outcomes over time.

Methods

The study population consisted of 1255 rrMM patients who were assigned to one of the following 6 treatment groups: immunomodulatory drug (IMiD)-based doublets, proteasome inhibitor (PI)-based doublets, daratumumab monotherapy, PI-IMiD-based triplets, monoclonal antibodies (mAbs)-based triplets, or other treatment.

Results

Use of triplet-based therapy regimen

SUBMITTER: Scheid C 

PROVIDER: S-EPMC7894176 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature